KalVista reports $13.7M Q3 net product revenue from EKTERLY launch; 937 patient start forms through Oct

KalVista Pharmaceuticals, Inc.

2025-Q3 EPS reported -$2.97 revenue$13,700,000

Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.
937 patient start forms received and 423 unique prescribers activated through Oct 31, 2025.
Cash and marketable securities of $309.2M; expects to fund through profitability.
EKTERLY approved in EU, Switzerland, and Australia; Germany launch initiated Oct 2025.
R&D expenses $12.0M (down from $18.7M); SG&A $46.5M (up from $24.8M) due to commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.